

### Amendments to the Claims

This listing of claims will replace all previous versions and listing of claims in the application:

- 1—43. (Canceled)
44. (Currently amended) An isolated polypeptide comprising:
- (a) the amino acid sequence of the polypeptide of SEQ ID NO: 290;
  - (b) the amino acid sequence of the polypeptide of SEQ ID NO: 290, lacking its associated signal peptide; or
  - (c) ~~the amino acid sequence of the extracellular domain of the polypeptide of SEQ ID NO: 290; or~~
  - (d) ~~the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209927.~~
45. (Previously presented) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide of SEQ ID NO: 290.
46. (Previously presented) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide of SEQ ID NO: 290, lacking its associated signal peptide.
- 47-48. (Cancelled)
49. (Previously presented) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209927.
50. (Previously presented) A chimeric polypeptide comprising a polypeptide according to Claim 44 fused to a heterologous polypeptide.
51. (Previously presented) The chimeric polypeptide of Claim 50, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.